



Bal Pharma Limited

10/08/2018

The Manager-Listing
BSE Limited
Mumbai.

The Manager-Listing
National Stock Exchange of India Ltd
Mumbai.

Dear Sir,

Sub : Out Come of the Board Meeting.

As already informed to the exchanges, the meeting of Board of Directors of the Company is held to day and the Board has *inter alia* transacted the following business.

1. Taken on record and approved the Un-Audited financial results of the Company for the quarter ended 30th June 2018. A copy of the approved standalone financial results along with the limited review report issued by the statutory auditors of the Company is enclosed with this communication.
2. Decided to close the Register of Members and Transfer books of the Company from 18/9/2018 to 22/09/2018 (both days inclusive) to ascertain the entitlement of Dividend and for the 31st Annual General Meeting of the Company scheduled on 22nd September 2018.
3. Decided to reappoint Dr.Subba Rao Prasanna as Whole Time Director of the Company for a further period of 2 years, which is however subject to the approval of the members at the ensuing Annual General Meeting.
4. Decided to appoint Mr.A.N.V.K Chaitanya as Chief Financial Office and Key Managerial personnel of the Company. Mr.Chaitanya is a Chartered Accountant with over 6 years of experience in finance and accounts, out of which 3 years are in the Company.

The meeting commenced at 4.00 P.M and concluded at 5.10 P.M on 10/8/2018.

Please take this intimation on record.

For Bal Pharma Ltd


Shailesh Siroya
Managing Director.



CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bengaluru - 560 052, India

Ph. : 91 - 80 - 41379500 Fax : 91 - 80 - 22354057 / 58

Email : info@balpharma.com Website : www.balpharma.com

CIN # L85110KA1987PLC008368

REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099. Ph: 41570813 / 19 Fax: 41570820



BAL PHARMA LIMITED
CIN: L85110KA1987PLC008363

Regd Office: 21-22, Bommasandra Industrial Area, Anekal Taluq, Bangalore - 560099.
Phone : 080 41379500, Fax: 22354057, email : investor@balpharma.com

STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2018

Sl No	Particulars	Standalone			
		QUARTER ENDED		YEAR ENDED	
		30.06.2018	31.03.2018	30.06.2017	31.03.2018
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Revenue from Operations	5,273.87	5,792.97	4,542.88	20,984.74
2	Other Income	76.28	-25.44	78.19	163.92
3	Total Revenue from operations (1+2)	5,350.14	5,767.53	4,621.07	21,148.66
4	Expenses				
a)	Cost of materials consumed	2,979.30	3,620.08	2,283.55	10,491.63
b)	Purchases of Stock-in-Trade	81.62	229.45	160.46	694.10
c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-90.75	-1,035.98	-483.60	-1,123.61
d)	Employee benefit expense	1,145.26	1,197.87	1,131.78	4,462.91
e)	Finance Costs	265.79	265.14	184.83	924.32
f)	Depreciation and amortization expense	143.09	196.27	144.80	672.80
g)	Other Expenses	700.63	1,025.75	1,099.73	4,181.04
	Total expenses	5,224.94	5,498.58	4,521.55	20,303.19
5	Profit before exceptional items and tax (3-4)	125.20	268.95	99.52	845.46
6	Exceptional items				
7	Profit Before Tax (5-6)	125.20	268.95	99.52	845.46
8	Tax Expense	-108.31	121.87	28.41	251.63
9	Net Profit for the period (7-8)	233.51	147.09	71.12	593.83
10	Other Comprehensive Income:				
a)	(i) Items that will be reclassified to Profit or Loss	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
b)	(i) Items that will not be reclassified to Profit or Loss	-	9.56	-12.88	-29.09
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
	Total other comprehensive Income	-	9.56	-12.88	-29.09
11	Total Comprehensive Income for the period (9+10)	233.51	156.65	58.24	564.74
12	Paid up Equity Share Capital (Face value of Rs. 10 per share)	1,417.24	1,417.24	1,417.24	1,417.24
13	Other Equity				
14	Earnings per share (of Rs. 10/- each)(not annualized)				
a)	Basic	1.65	1.11	0.50	3.98
b)	Diluted	1.65	1.11	0.50	3.98

Notes:


- The above Un-Audited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 10th August, 2018. The financial results are subjected to limited review by the Statutory Auditors of the Company.
- The Un-Audited financial results have been prepared in accordance with the Ind AS , notified under the Companies (Indian Accounting Standards) Rules, 2015.
- As per Regulation 33 of SEBI (LODR) Regulations, Company opted to submit standalone financials to the stock exchanges. However, unabridged financial statements will be uploaded on our website.
- As the Company deals with single product i.e., pharmaceuticals, segment wise figures are not furnished.
- Effective April 1, 2018 the Company adopted Ind AS 115 "Revenue from Contracts with Customers" as such the effect of adaption is insignificant on financial statement and hence accordingly the comparatives have not been retrospectively adjusted.
- The Figures for the corresponding previous period have been regrouped/ restated, wherever necessary.


Place: Bengaluru

Date: 10.08.2018

For Bal Pharma Limited

Shallesh D Siroya
Managing Director





INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF STANDALONE INTERIM FINANCIAL RESULTS


To
Board of Directors of **M/s. Bal Pharma Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of **M/s. Bal Pharma Limited** ("The Company") for the quarter ended June 30, 2018 ("The Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

The statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial reporting" ("Ind AS 34"), Prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the standalone financial results based on our review.

2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity*, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.


3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in



accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

4. The comparative financial information of the company for the quarter ended June 30, 2017 prepared in accordance with Ind AS included in this Statement has been reviewed by the predecessor auditor. The report of the predecessor auditor on these comparative financial information dated 11th September, 2017 expressed an unmodified opinion.

Place: Bengaluru
Date: 10th August, 2018



For NSVM & Associates.
Chartered Accountants
FRN: 010072S

A handwritten signature in black ink, appearing to read "G.C.S MANI".

G.C.S MANI
Partner
M.No: 036508